Quick Order

CD137 / 4-1BB / TNFRSF9 Antibody, Rabbit PAb, Antigen Affinity Purified

    DatasheetReviewsRelated ProductsProtocols
    Human 4-1BB/TNFRSF9 Antibody Product Information
    Immunogen:Recombinant Human CD137 / 4-1BB protein (Catalog#10041-H08H)
    Clone ID:
    Ig Type:Rabbit IgG
    Concentration:
    Formulation:0.2 μm filtered solution in PBS
    Preparation:Produced in rabbits immunized with purified, recombinant Human CD137 / 4-1BB (rh CD137 / 4-1BB; Catalog#10041-H08H; NP_001552.2; Met 1-Gln 186). CD137 / 4-1BB specific IgG was purified by Human CD137 / 4-1BB affinity chromatography.
    Other 4-1BB/TNFRSF9 Antibody Products
    Reactivity: Human  
    Application: ELISA  
      10041-T16-100
      10041-T16-50
      10041-T16-200
      100 µg 
      50 µg 
      200 µg 
      Add to Cart
      Reactivity: Human  
      Application: ELISA  
        10041-RP01-200
        10041-RP01-100
        10041-RP01-400
        200 µg 
        100 µg 
         
        Add to Cart
        4-1BB/TNFRSF9/CD137 Background

        CD137 (also known as 4-1BB) is a surface co-stimulatory glycoprotein originally described as present on activated T lymphocytes, which belongs to the tumor necrosis factor (TNF) receptor superfamily. It is expressed mainly on activated CD4+ and CD8+ T cells, and binds to a high-affinity ligand (4-1BBL) expressed on several antigen-presenting cells such as macrophages and activated B cells. Upon ligand binding, 4-1BB is associated with the tumor necrosis factor receptor–associated factors (TRAFs), the adaptor protein which mediates downstream signaling events including the activation of NF-kappaB and cytokine production. 4-1BB signaling either by binding to 4-1BBL or by antibody ligation delivers signals for T-cell activation and growth, as well as monocyte proliferation and B-cell survival, and plays an important role in the amplification of T cell-mediated immune responses. In addition, CD137 and CD137L are expressed in different human primary tumor tissues, suggesting that they may influence the progression of tumors. Crosslinking of CD137 on activated T cells has shown promise in enhancing anti-tumor immune responses in murine models, and agonistic anti-CD137 antibodies are currently being tested in phase I clinical trials.

        Immune Checkpoint
        Immune Checkpoint Detection: Antibodies   Immune Checkpoint Detection: ELISA Antibodies
        Immune Checkpoint Proteins
        Immune Checkpoint Targets   Co-stimulatory Immune Checkpoint Targets

        Immunotherapy   Cancer Immunotherapy   Targeted Therapy

        Human 4-1BB/TNFRSF9/CD137 References
      • Sica G, et al. (1999) Biochemical and immunological characteristics of 4-1BB (CD137) receptor and ligand and potential applications in cancer therapy. Arch Immunol Ther Exp (Warsz). 47(5): 275-9.
      • Nam KO, et al. (2005) The therapeutic potential of 4-1BB (CD137) in cancer. Curr Cancer Drug Targets. 5(5): 357-63.
      • Wang Q, et al. (2008) Analysis of CD137 and CD137L expression in human primary tumor tissues. Croat Med J. 49(2): 192-200.
      • Melero I, et al. (2008) Multi-layered action mechanisms of CD137 (4-1BB)-targeted immunotherapies. Trends Pharmacol Sci. 29(8): 383-90.
      • Thum E, et al. (2009) CD137, implications in immunity and potential for therapy. Front Biosci. 14: 4173-88.
      • Product nameProduct name
        Size / Price
        Catalog: 10041-RP02-100
        List Price: 
        Price:      (You Save: )

        Datasheet & Documentation

        All information of our products is subject to change without notice. Please refer to COA enclosed in shipped package for the newest information.
        Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"